COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s): CSCI

Healthcare Biotechnology

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

TSX:CSCI - Post by User

COSCIENS Biopharma Inc > Limitations according to one article:

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Aug 25, 2024 1:29pm

42 Views

Post# 36195267

RE:Limitations according to one article:

"Unfortunately, very high cost and the potential drug-to-drug interactions limit the use of the test."

If Macimorelin was proven as a standalone test eliminating the need for a second test that could justify a premium price. The current pediatric trial is testing that and we will see the results. The dosage has also been doubled in the pediatric trial to 1 mg/kg vs. adult dosing which could further optimize the results and appropriate treatment. Misdiagnosis can be costly. Apparently the pediatric market is also less crowded than the adult market and an ideal market for an oral drug as opposed using an intervenous drug on a kid. I've also seen the possibility of orphan drug pricing mentioned for pediatrics. I don't know what the production costs for the drug are; but with approval for adults and children there could be economies of scale and a price reduction if necessary.

Can the company address potential drug-to-drug interactions? Maybe with time. The drug has been used in a commercial setting and I haven't seen any issues. Gilles should know as an insider of AEZS and after having watched the launch of the drug. Those contraindicated don't have to use the test.

prophetoffactz wrote: Macimorelin is CSCI's test.
Are these issues solvable?

"The other tests suggested by guidelines are the glucagon stimulation test (GST) and the macimorelin test [3]. Macimorelin is a synthetic GH secretagog (GHS) [7] that has the advantage to be orally administered, with few side effects [8]. Unfortunately, very high cost and the potential drug-to-drug interactions limit the use of the test. Moreover, the announcement in August 2022 that macimorelin should be temporarily discontinued in the commercial market of US makes this test less used in clinical practice..."

Once upon a time: the glucagon stimulation test in diagnosing adult GH deficiency - PMC (nih.gov)